Helicobacter pylori

Target from H. Pylori Genome Alliance Announced

Published in Cancer Weekly, April 21st, 1997

Genome Therapeutics Corp., Waltham, Massachusetts, and Astra Research Center Boston, Cambridge, Massachusetts, announced that an undisclosed novel target identified in their Helicobacter pylori genome research alliance entered high-throughput screening for drug candidates.

GTC's alliance with Astra AB, to identify and develop novel anti-infectives to treat H. pylori, began in September 1995. Initiation of high-throughput drug screening triggers a research milestone payment, the third research milestone achieved by GTC in the alliance.

"We are very pleased with the progress of our collaboration with Astra," stated Robert J. Hennessey,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry